
Novartis Licenses CAR-T Patents in Separate Deals
Novartis entered separate license agreements with bluebird bio and Celyad for patents related to the manufacture of CAR-T cells.
On May 2, 2017, bluebird bio and Celyad both announced license agreements with Novartis for separate chimeric antigen receptor T cell (CAR-T) patents. The deal with bluebird involves patents related to the company’s lentiviral vector technology to develop and commercialize CAR-T therapies for oncology, including CTL019, Novartis’s anti-CD19 CAR T investigational therapy. While the financial terms of the agreement were not disclosed, bluebird said in a
In a
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.